Quantcast

Latest Biomedical Advanced Research and Development Authority Stories

2014-06-17 12:28:42

MERIDEN, Conn., June 17, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that BARDA, within the U.S. Department of Health and Human Services, exercised Option Period 2 of its contract with the Company (contract number HHS0100200900106C) to support development, scale-up and expanded licensure of the Company's influenza vaccines, Flublok® (seasonal) and Panblok® (pandemic). Option Period 2 has a budget of $50.6 million and will run through December 31, 2015. The...

2014-05-29 12:28:35

ANNAPOLIS, Md., May 29, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company's SparVax(®) anthrax vaccine program were presented at the 114(th) General Meeting of the American Society for Microbiology (ASM), held recently in Boston, Massachusetts. In a poster presentation entitled "Evidence Correlating Changes in Structure and Biological Activity for a Recombinant Protective Antigen (rPA) Anthrax Vaccine," Dr. Bradford Powell,...

2014-05-12 08:31:13

PRINCETON, N.J., May 12, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the first quarter ended March 31, 2014. Soligenix's revenues for the quarter ended March 31, 2014 were $0.9 million as...

2014-05-02 12:26:44

CLEVELAND, May 2, 2014 /PRNewswire/ -- Arteriocyte, Inc., a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts, announced approval from the Federal Drug Administration (FDA) to initiate a Phase I, clinical trial using its MAGELLAN(®) Bio-Bandage((TM) )technology in the treatment of Acute Deep Partial Thickness Thermal Injuries. The FDA Investigational Device Exemption (IDE 15921) allows Arteriocyte to initiate clinical evaluation of Autologous...

2014-04-08 08:32:45

Appoints Larry Gyenes, Formerly of Columbia Laboratories, as Chief Financial Officer PINE BROOK, N.J., April 8, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced that it has completed validation of the commercial manufacturing process for ETI-204, an anthrax antitoxin currently undergoing Phase 3 clinical trials in healthy volunteers....

2014-04-07 08:32:23

ANNAPOLIS, Md., April 7, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax(®) anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which...

2014-04-01 16:25:27

ANNAPOLIS, Md., April 1, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax(® )next-generation anthrax vaccine program were recently presented at the 8(th) Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's...

2014-03-26 08:28:41

PRINCETON, N.J., March 26, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013. Soligenix's revenues for the year ended were $3.2 million as compared to $3.1 million for...

2014-03-18 08:33:33

New Contract Reflects Successful Strategy to Diversify Customer Base ROCKVILLE, Md., March 18, 2014 /PRNewswire/ -- The EMMES Corporation today announced that it has been awarded an indefinite delivery, indefinite quantity (IDIQ) contract to become part of a clinical studies network established by the Biomedical Advanced Research and Development Authority (BARDA) to perform studies needed to develop medical countermeasures against agents of bioterrorism, pandemic influenza, and other...

2014-03-12 16:25:45

HINCKLEY, Ohio, March 12, 2014 /PRNewswire/ -- Clinical Research Management, Inc. (ClinicalRM) - a full-service Contract Research Organization (CRO) providing support for basic and applied research, clinical trials, and regulatory support - announced today it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). With this contract award ClinicalRM becomes part of a clinical studies network being established by BARDA to support development of...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related